Seagen Stock Price

2.59 (1.76%)
Upgrade to Real-Time
Regular Market


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Seagen Inc SGEN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
2.59 1.76% 150.09 12:12:00
Open Price Low Price High Price Close Price Prev Close
145.94 144.91 150.18 147.50
Bid Price Ask Price Spread News
149.99 150.09 0.10 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
9,169 657,075 $ 148.82 $ 97,784,548 895,612 133.20 - 213.94
Last Trade Time Type Quantity Stock Price Currency
12:12:00 141 $ 150.09 USD

Seagen Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 27.24B 181.48M 65.91M $ 2.18B $ 628.73M 3.30 40.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -44.05k 1.30%

more financials information »

Seagen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SGEN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week138.53150.18133.51142.71974,19511.568.34%
1 Month147.26150.18133.20141.98925,9692.831.92%
3 Months157.05159.3499133.20145.761,038,521-6.96-4.43%
6 Months177.25202.60133.20161.691,048,394-27.16-15.32%
1 Year162.41213.94133.20165.681,039,261-12.32-7.59%
3 Years58.67213.9450.71114.171,003,40691.42155.82%
5 Years34.13213.9434.0091.57983,238115.96339.76%

Seagen Description

Seagen Inc is a biotech firm focused on developing antibody-drug conjugates. The company's lead product, Adcetris, has received approval for advanced front-line, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. Other approved products include Padcev (bladder cancer) and Tukysa (breast cancer). The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.